Skip to main content

Table 4 Treatment-Emergent Cardiovascular Adverse Events

From: Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies

  Eptinezumab 100 mg Eptinezumab 300 mg Eptinezumab 1000 mg Placebo
Patients, n (%) N = 701 N = 695 N = 81 N = 791
Cardiac disorders 6 (0.9) 8 (1. 2) 2 (2.5) 8 (1.0)
 Bradycardia 0 2 (0.3) 0 0
 Palpitations 1 (0.1) 2 (0.3) 0 3 (0.4)
 Tachycardia 1 (0.1) 2 (0.3) 0 1 (0.1)
 Atrial fibrillation 0 1 (0.1) 0 1 (0.1)
 Atrioventricular block first degree 2 (0.3) 1 (0.1) 0 1 (0.1)
 Bundle branch block right 0 0 1 (1.2) 1 (0.1)
 Nodal rhythm 0 0 1 (1.2) 0
 Sinus bradycardia 0 0 0 1 (0.1)
 Sinus tachycardia 1 (0.1) 0 0 0
 Supraventricular extrasystoles 1 (0.1) 0 0 0
Investigationsa 37 (5.3) 28 (4.0) 10 (12.3) 39 (4.9)
 Increased blood pressure 7 (1.0) 3 (0.4) 1 (1.2) 5 (0.6)
 Increased heart rate 0 1 (0.1) 0 0
 Increased systolic blood pressure 1 (0.1) 0 0 0
 Abnormal electrocardiogram Q wave 1 (0.1) 0 1 (1.2) 0
 Prolonged electrocardiogram QT 0 0 3 (3.7) 1 (0.1)
Vascular disorders 11 (1.6) 10 (1.4) 1 (1.2) 8 (1.0)
 Hot flush 2 (0.3) 4 (0.6) 1 (1.2) 0
 Hypertension 4 (0.6) 3 (0.4) 0 6 (0.8)
 Flushing 1 (0.1) 2 (0.3) 0 1 (0.1)
 Hypotension 1 (0.1) 1 (0.1) 0 0
 Prehypertension 0 0 0 1 (0.1)
  1. aNot limited to CV-related investigations. CV Cardiovascular